StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Up 1.8 %

Enzo Biochem stock opened at $1.15 on Thursday. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50. The stock’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.12.

Enzo Biochem Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be given a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a yield of 34.78%. The ex-dividend date of this dividend is Friday, November 15th.

Institutional Trading of Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd raised its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 28,262 shares of the medical research company’s stock after acquiring an additional 13,735 shares during the period. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 as of its most recent SEC filing. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.